BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Greef Roderick De sold 4,509 shares of the business’s stock in a transaction dated Friday, February 19th. The stock was sold at an average price of $40.76, for a total transaction of $183,786.84. Following the completion of the sale, the chief financial officer now owns 161,033 shares in the company, valued at $6,563,705.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Greef Roderick De also recently made the following trade(s):
- On Wednesday, February 17th, Greef Roderick De sold 4,424 shares of BioLife Solutions stock. The shares were sold at an average price of $41.55, for a total transaction of $183,817.20.
NASDAQ BLFS opened at $40.92 on Monday. The business’s 50-day moving average price is $40.98 and its 200 day moving average price is $32.59. BioLife Solutions, Inc. has a twelve month low of $7.37 and a twelve month high of $47.22. The company has a market capitalization of $1.34 billion, a PE ratio of -56.05, a price-to-earnings-growth ratio of 50.41 and a beta of 1.55.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in shares of BioLife Solutions in the fourth quarter worth approximately $31,000. BNP Paribas Arbitrage SA raised its stake in BioLife Solutions by 1,358.5% during the third quarter. BNP Paribas Arbitrage SA now owns 2,990 shares of the medical equipment provider’s stock worth $87,000 after purchasing an additional 2,785 shares during the period. Parallel Advisors LLC acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $113,000. Citigroup Inc. grew its stake in shares of BioLife Solutions by 265.7% during the 4th quarter. Citigroup Inc. now owns 3,156 shares of the medical equipment provider’s stock valued at $126,000 after buying an additional 2,293 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of BioLife Solutions during the 4th quarter valued at $194,000. 67.66% of the stock is owned by institutional investors.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Story: What is the formula for calculating total return?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.